

Manuel F Ugarte-Gil

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8008231/manuel-f-ugarte-gil-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118
papers

1,330
citations

19
h-index

33
g-index

155
ext. papers

2,119
ext. citations

3.5
avg, IF

4.77
L-index

#	Paper	IF	Citations
118	Epidemiology of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 799-814	5.1	92
117	Disease features and outcomes among US lupus patients of Hispanic origin and their Mestizo counterpart in Latina America. <i>Arthritis Research and Therapy</i> , 2014 , 16,	5.7	78
116	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1019-23	2.4	64
115	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2071-2074	2.4	62
114	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL,)-Pan-American League of Associations of Rheumatology (PANLAR). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1549-1557	2.4	57
113	Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007 , 26, 1831-5	3.9	57
112	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1137-1146	2.4	49
111	Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2021 , 3, e243-e245	14.2	43
110	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 659-666	5.1	40
109	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021 , 7,	5.9	36
108	Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 675-83	5.3	34
107	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 734-736	2.4	32
106	Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. <i>Lupus</i> , 2019 , 28, 1101-1110	2.6	26
105	High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients. <i>Lupus</i> , 2014 , 23, 969-74	2.6	26
104	Abatacept for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 493-9	5.9	25
103	Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 915-931	5.1	25
102	Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e613-e615	14.2	23

101	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	20
100	Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2017 , 36, 845-852	3.9	17
99	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. <i>RMD Open</i> , 2020 , 6,	5.9	17
98	Factors associated with health-related quality of life in Peruvian patients with systemic lupus erythematosus. <i>Lupus</i> , 2018 , 27, 913-919	2.6	16
97	Circulating CD4+CD28null and extra-thymic CD4+CD8+ double positive T cells are independently associated with disease damage in systemic lupus erythematosus patients. <i>Lupus</i> , 2016 , 25, 233-40	2.6	15
96	Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. <i>Lupus</i> , 2019 , 28, 423-426	2.6	14
95	Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. <i>Lupus</i> , 2018 , 27, 536-544	2.6	13
94	Circulating naive and memory CD4+ T cells and metabolic syndrome in patients with systemic lupus erythematosus: data from a primarily Mestizo population. <i>Rheumatology</i> , 2015 , 54, 1302-7	3.9	13
93	Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. <i>Rheumatology</i> , 2016 , 55, 436-40	3.9	12
92	Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. <i>RMD Open</i> , 2019 , 5, e000955	5.9	12
91	Lupus: the new epidemic. <i>Lupus</i> , 2019 , 28, 1031-1050	2.6	11
90	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e855-e864	14.2	11
89	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2021 , 3, e707-e714	14.2	11
88	Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort. <i>Arthritis Care and Research</i> , 2020 , 72, 1159-1162	4.7	10
87	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 1299-1308	4.1	9
86	Systemic lupus erythematosus: a therapeutic challenge for the XXI century. <i>Clinical Rheumatology</i> , 2014 , 33, 441-50	3.9	9
85	Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. <i>Rheumatology</i> , 2021 , 60, S168-S176	3.9	9
84	Access to an optimal treatment. Current situation. <i>Clinical Rheumatology</i> , 2015 , 34 Suppl 1, S59-66	3.9	8

83	Applying the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Lupus Criteria to Patients From the LUMINA Cohort: Results From the Multiethnic, Multicenter US Cohort. <i>Arthritis Care and Research</i> , 2021 , 73, 1451-1455	4.7	8
82	Discrepant Perception of Lupus Disease Activity: A Comparison Between Patients and Physicians Disease Activity Scores. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, S165-S169	1.1	8
81	Genetics and genomics in Peru: Clinical and research perspective. <i>Molecular Genetics & Genomic Medicine</i> , 2018 , 6, 873-886	2.3	8
80	Hypokalemic Paralysis: A Hidden Card of Several Autoimmune Diseases. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2017 , 10, 1179544117722763	2.3	7
79	Genetics of ANCA-associated Vasculitides. <i>Current Rheumatology Reports</i> , 2014 , 16, 428	4.9	7
78	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
77	Systemic lupus erythematosus: The search for the ideal biomarker. <i>Lupus</i> , 2021 , 30, 181-203	2.6	7
76	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. <i>Clinical Rheumatology</i> , 2019 , 38, 2737-2746	3.9	6
75	Remission or low disease activity as a target in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e3	2.4	6
74	Achievement of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Criteria for Systemic Lupus Erythematosus and Amount of Damage Accrual: Results From a Multiethnic Multicenter Cohort. <i>Arthritis Care and Research</i> , 2021 , 73, 1038-1040	4.7	6
73	A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. <i>Lupus</i> , 2018 , 27, 1753-1754	2.6	6
72	Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort. <i>Frontiers in Immunology</i> , 2021 , 12, 700921	8.4	6
71	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 199-203	5.3	5
70	Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients. <i>Lupus</i> , 2019 , 28, 1344-1349	2.6	5
69	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
68	Serum uric acid is associated with damage in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7, e000366	4.6	4
67	Factors associated with disease expression patterns in systemic lupus erythematosus patients: results from LUMINA (LXXVII), a multiethnic US cohort. <i>Lupus</i> , 2017 , 26, 650-655	2.6	4
66	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.. <i>Lancet Rheumatology, The</i> , 2022 ,	14.2	4

65	Predictors of renal damage in systemic lupus erythematosus patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). <i>RMD Open</i> , 2020 , 6,	5.9	4
64	Reliability of Visual Analog Scale and Numeric Rating Scale for the Assessment of Disease Activity in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, S170-S173	1.1	4
63	COVID-19 and Its Potential Effect on Patients With Rheumatic Diseases in Latin America. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, 215-217	1.1	4
62	Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. <i>Clinical Rheumatology</i> , 2021 , 40, 4725-4734	3.9	4
61	Treat to target in systemic lupus erythematosus: a commentary. <i>Clinical Rheumatology</i> , 2016 , 35, 1903-1907	3.9	4
60	Prolactin levels are associated with a pro-inflammatory body mass distribution among women with systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 808-814	2.6	3
59	Gorham-Stout Syndrome: A Phantom Bone Disease Treated With Bisphosphonates. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, e135-e136	1.1	3
58	Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 369-409	4.7	3
57	Current status of the rheumatologists workforce in Latin America: a PANLAR collaborative study. <i>Clinical Rheumatology</i> , 2021 , 40, 2913-2920	3.9	3
56	Peripheral CD4+CD28null T-cells as predictors of damage in systemic lupus erythematosus patients. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 1008-1013	2.2	3
55	Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	2
54	Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. <i>Rheumatology International</i> , 2021 , 1	3.6	2
53	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry		2
52	Performance of the 2017 American College of Rheumatology/European League Against Rheumatism Provisional Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Peruvian Tertiary Care Center. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	2
51	Socioeconomic Aspects of Systemic Lupus Erythematosus 2016 , 39-42		2
50	Design of an algorithm for the diagnostic approach of patients with joint pain. <i>Clinical Rheumatology</i> , 2021 , 40, 1581-1591	3.9	2
49	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	2
48	Defining Quality of Rheumatologic Care: Peru. <i>Journal of Clinical Rheumatology</i> , 2017 , 23, 212-214	1.1	1

47	FRI0284 High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A470.2-A470	2.4	1
46	ANCA-Associated Vasculitis in Latin America: A Systematic Literature Review: About Their Epidemiology and Their Clinical Features.. <i>Journal of Clinical Rheumatology</i> , 2022 , 28, 44-51	1.1	1
45	The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus.. <i>Lupus</i> , 2022 , 9612033221074580	2.6	1
44	AB0449 IMPACT OF REMISSION AND LOW DISEASE ACTIVITY (LDA) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS: A SYSTEMATIC LITERATURE REVIEW (SLR). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1523-1523	2.4	1
43	Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	1
42	Survival in ANCA-Associated Vasculitides in a Peruvian Center: 28 Years of Experience. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, S252-S258	1.1	1
41	OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA). <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 173.2-175	2.4	1
40	OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 2.1-4	2.4	1
39	Impact of COVID-19 Pandemic on Rheumatology Practice in Latin America. <i>Journal of Rheumatology</i> , 2021 , 48, 1616-1622	4.1	1
38	Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. <i>Clinical Rheumatology</i> , 2019 , 38, 1139-1146	3.9	1
37	Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE" by Whittall Garcia. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
36	Correspondence on Q022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis by Joanna C Robson and Q022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis by Joanna C Robson	2.4	1
35	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. <i>Lupus</i> , 2020 , 29, 1140-1145	2.6	0
34	Demographic and Clinical Features of ANCA-Associated Vasculitides in a Peruvian Tertiary Center. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, S246-S251	1.1	0
33	Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.. <i>Lupus</i> , 2022 , 9612033211061481	2.6	0
32	Different epidemiologic profiles of systemic vasculitis between Brazil and Peru-preliminary results in two referral centers from both countries.. <i>Clinical Rheumatology</i> , 2022 , 41, 635	3.9	0
31	Health-Related Quality of Life and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. <i>Lupus</i> , 2021 , 30, 2157-2161	2.6	0
30	POS1190 EXPECTATIONS AND POTENTIAL CONCERNS OF PATIENTS WITH AUTOIMMUNE AND RHEUMATIC DISEASES REGARDING VACCINATION AGAINST SARS-CoV-2 (COVID-19): THE WORLDWIDE ONLINE VAXICOV STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 877-877	2.4	0

29	Rheumatology and psychiatry: allies in times of COVID-19. <i>Clinical Rheumatology</i> , 2021 , 40, 3363-3367	3.9	o
28	Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort: The LUMINA (Lupus in Minorities: Nature vs. Nurture) Experience (LUMINA LXXXII). <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 55-64	2.4	o
27	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. <i>Lupus</i> , 2021 , 961203320988586	2.6	o
26	The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey.. <i>Rheumatology Advances in Practice</i> , 2022 , 6, rkac001	1.1	o
25	LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.. <i>Lupus Science and Medicine</i> , 2022 , 9,	4.6	o
24	Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients.. <i>Lupus</i> , 2021 , 9612033211063798	2.6	o
23	A Practical Roadmap for Writing of Medical Scientific Publications. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 314-317	1.1	
22	Coronary and Aortic Involvement as Initial Manifestations of Possible Giant Cell Arteritis in a Patient Without Cardiovascular Comorbidities. <i>Journal of Clinical Rheumatology</i> , 2016 , 22, 386	1.1	
21	Is Low Disease Activity Sufficient as a Target in Systemic Lupus Erythematosus? Comment on the Article by Petri et al. <i>Arthritis and Rheumatology</i> , 2018 , 70, 2098-2099	9.5	
20	AB0529 Prevalence of Circulating CD4+ Cd28null T-Cells is Independently Associated with Disease Damage in Systemic Lupus Erythematosus (SLE) Patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 981.2-981	2.4	
19	FRI0034 Functional DRB1 Shared Epitope Subtypes Correlate with Joint Damage in Latin American Rheumatoid Arthritis Patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 393.1-393	2.4	
18	FRI0425 Prevalence of Circulating Naive CD4+ T-Cells and Memory/Naive CD4+ T-Cells Ratio Are Independently Associated with the Metabolic Syndrome (METS) in Systemic Lupus Erythematosus (SLE) Patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 540.2-541	2.4	
17	FRI0121 Concordance of 6 composite disease activity measures in a peruvian population with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 351.2-351	2.4	
16	Is there an effective treatment for late-onset systemic lupus erythematosus?. <i>Aging Health</i> , 2013 , 9, 437-450		
15	AB0590 Prolactin Levels are Associated with a Pro-Inflammatory Body Mass Distribution Among Systemic Lupus Erythematosus Female Patients. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1097.2-1097 ² .4		
14	Susac Syndrome 2008 , 117-120		
13	SAT0237 THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) FRAILTY INDEX (SLICC-FI) PREDICTS DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS. DATA FROM A LATIN AMERICAN MESTIZO COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1061.1-1062	2.4	
12	THU0316 VALIDATION OF ACR/EULAR PROVISIONAL CLASSIFICATION CRITERIA FOR ANCA-ASSOCIATED VASCULITIS IN A LATIN-AMERICAN TERTIARY CENTER. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 387.2-387	2.4	

11	AB0448 IMPACT OF REMISSION ON DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS: A SYSTEMATIC LITERATURE REVIEW (SLR). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1522.1-1522	2.4
10	THU0286 THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) FRAILTY INDEX (SLICC-FI) PREDICTS DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS. DATA FROM A MULTI-ETHNIC, MULTI-CENTER US LUPUS COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 370.2-370	2.4
9	AB1270 RHEUMATOLOGY WORKFORCE IN LATIN AMERICA: TRAINING AND CURRENT STATUS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1926.1-1926	2.4
8	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. <i>Rheumatology</i> , 2020 , 59, e165-e168	3.9
7	Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. <i>Lupus</i> , 2020 , 29, 1644-1649	2.6
6	Response to: Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis by Singer. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4
5	Interest on the internet for systemic lupus erythematosus: Analysis of Google Trends in Latin American countries. <i>Lupus</i> , 2021 , 30, 1342-1346	2.6
4	OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 177-178	2.4
3	Preconception, pregnancy, and lactation in systemic lupus erythematosus patients. <i>Revista Colombiana De Reumatología</i> , 2021 , 28, 156-156	0.2
2	Rapidly progressive interstitial lung disease-associated hypomyopathic dermatomyositis complicated with pneumomediastinum: A case-based review. <i>Revista Colombiana De Reumatología</i> , 2021 ,	0.2
1	PANLAR-Journal of Clinical Rheumatology 2021 Supplement. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, S147	1.1